Drägerwerk cleared FDA hurdle: mwb research raised target for Drägerwerk stock to EUR 135.00

Published on 10/14/2026 at 09:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sales rose 8.60 percent in second quarter of 2026. Drägerwerk stock costs EUR 115.30 on October 14, 2026 versus EUR 115.00 Xetra close.

Regulatory clearance and earnings path

On October 9, 2026, mwb research lifted its target from EUR 130.00 to EUR 135.00 after FDA clearance.
Second-quarter 2026 sales rose 8.60 percent to EUR 847.30 million.
Drägerwerk stock traded at EUR 115.30 at 9:38 a.m. CEST at Lang & Schwarz on October 14, 2026, 0.26 percent above the Xetra close of October 13, 2026.

Aquarellmalerei der Lübecker Altstadt mit Holstentor und Flussreflexionen in Pastellfarben — Drägerwerk AG & Co. KGaA Firmensitz Lübeck historische Altstadt Holstentor Aquarellmalerei Trave DE0005550636, Illustration mit AI erstellt.

Drägerwerk (ISIN DE0005550636) was trading at EUR 115.30 at Lang & Schwarz on October 14, 2026 at 9:38 a.m. CEST, 0.26 percent above the Xetra close of October 13, 2026. The medical technology group cleared a regulatory hurdle in the United States, and FinanzNachrichten.de reported on October 9, 2026 that mwb research raised its price target from EUR 130.00 to EUR 135.00 after FDA clearance for the IACS VG8.1 monitoring system.

Regulatory hurdle ends

The FDA clearance lifted restrictions linked to a 2020 warning letter and reopened Dräger's US patient-monitoring portfolio for markets that depend on FDA approvals, according to FinanzNachrichten.de. The report said short-term earnings effects should be limited, while rebuilding US sales capacity and customer acquisition could improve the medium-term growth profile.

Three events shape the story

Dräger's second-quarter 2026 sales reached EUR 847.30 million, up 8.60 percent from EUR 779.99 million a year earlier, while EBITDA rose to EUR 79.80 million from EUR 52.00 million, according to ResearchHub. Its chronology also records an EUR 130.00 target on August 31, 2026 and the later EUR 135.00 target on October 9, 2026.

What does clearance change?

The earnings backdrop gives the regulatory event a measurable context. Dräger's investor-relations guidance for fiscal year 2026 calls for currency-adjusted revenue growth of 2.00 to 6.00 percent and an EBIT margin of 5.00 to 7.50 percent, while DVA is projected at EUR 20.00 million to EUR 120.00 million, according to Drägerwerk. The FDA decision therefore matters mainly through future sales execution rather than an immediate earnings boost.

Dates for the next proof points

ResearchHub lists the third-quarter results for October 29, 2026 and the Capital Markets Day in Lübeck for November 18, 2026. Those dates should provide figures on order momentum, margin progress and the response of the US monitoring business.

Price and market context

At 9:38 a.m. CEST, Drägerwerk stock was trading at EUR 115.30 at Lang & Schwarz on October 14, 2026, 0.26 percent above the Xetra close of October 13, 2026 at EUR 115.00. The primary Xetra quote had a 52-week range of EUR 59.90 to EUR 125.40, while market capitalization stood at EUR 2.2 billion as of October 14, 2026. The further course of trading is shown by the continuously updated real-time quote of Drägerwerk stock.